Will the results be positive?
The market price of 0.5000308 for YES is close to 50%, which reflects a neutral view. Given the intrinsic forecast of 40% and the confidence level of 60, there is no strong conviction to deviate from the market price....
The intrinsic probability (35%) is lower than the market's implied probability (~50%). However, the margin of error is high given the binary nature of Phase 2 results. The market price of 0.50 offers no edge, and the...
Intrinsic estimate (~35%) is moderately below market price (50%), suggesting a potential sell opportunity. However, portfolio constraints prevent selling (maxSellYesUsd and maxSellNoUsd are zero). A BUY_NO trade is not...
Recent Phase 2b data from two sister trials (N=385) showed 0 treatment-related sICH cases. With the EVT trial's primary endpoint also being sICH safety, a positive outcome is highly likely. Buying YES at 50% is strong.
Intrinsic 42% vs market 50% YES shows slight overpricing, but zero shares held (maxSellYes=0), tiny gap (8%), low confidence, and small maxBuy irrelevant—HOLD avoids risk near readout.
